CNC vs IMRX · P/E 8.4, rev $163.07B vs $124.2M cap
Centene Corp (CNC) versus Immuneering Corp (IMRX) — a side-by-side from cached financials, not a winner call.
Centene Corp (CNC) is a healthcare plans company listed on US.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
Latest reported CNC revenue for 2024-12-31 was $163.07B. Net income was $3.29B. Revenue was up 5.9% from 2023-12-31 to 2024-12-31. CNC currently screens at market cap $28.19B and trailing P/E 8.4.
Latest reported IMRX revenue for 2023-12-31 was $0. Net income was -$53.5M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. IMRX currently screens at market cap $124.2M.
CNC currently screens at market cap $28.19B and trailing P/E 8.4. IMRX currently screens at market cap $124.2M.
Not investment advice. Open the CNC and IMRX stock pages for the full models.
Not investment advice.